Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
NEW YORK, May 08, 2018 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc. (NASDAQ:MYGN) who purchased shares between August 13, 2014 and March 12, 2018. The action, which was filed in the United States District Court for the District of Utah, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
Shareholders have until June 19, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/myriad-genetics-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
